Hospitalization for hemorrhage among warfarin recipients prescribed amiodarone

American Journal of Cardiology

Volumn 112, Issue 3, 2013, Pages 420-423

  Lam, Jason ^a   Gomes, Tara ^b,c   Juurlink, David N ^c,d,e,f   Mamdani, Muhammad M ^b,c,g   Pullenayegum, Eleanor M ^h   Kearon, Clive ^h   Spencer, Frederick A ^h   Paterson, Michael ^c,e,h,i   Zheng, Hong ^c   Holbrook, Anne M ^b,h,i  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f Institute of Clinical Evaluative Sciences   (Canada)

^g ST MICHAEL'S HOSPITAL   (Canada)

^h MCMASTER UNIVERSITY   (Canada)

ⁱ CENTRE FOR EVALUATION OF MEDICINES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; WARFARIN;

AGED; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; PROPENSITY SCORE; RETROSPECTIVE STUDY; UPPER GASTROINTESTINAL BLEEDING;

AGED; ALGORITHMS; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; COHORT STUDIES; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HEMORRHAGE; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; MALE; ONTARIO; RETROSPECTIVE STUDIES; WARFARIN;

EID: 84880324747     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2013.03.051     Document Type: Article

References (22)

1. C.A. Sanoski, and J.L. Bauman Clinical observations with the amiodarone/warfarin interaction: dosing relationships with long-term therapy Chest 121 2002 19 23
2. J. Hirsh, V. Fuster, J. Ansell, and J.L. Halperin American Heart Association/American College of Cardiology Foundation guide to warfarin therapy J Am Coll Cardiol 41 2003 1633 1652
3. S.B. Edwin, D.L. Jennings, and J.S. Kalus An evaluation of the early pharmacodynamic response after simultaneous initiation of warfarin and amiodarone J Clin Pharmacol 50 2010 693 698
4. Y. Lu, K.A. Won, B.J. Nelson, D. Qi, D.J. Rausch, and R.W. Asinger Characteristics of the amiodarone-warfarin interaction during long-term follow-up Am J Health Syst Pharm 65 2008 947 952
5. S. Almog, N. Shafran, H. Halkin, P. Weiss, Z. Farfel, U. Martinowitz, and H. Bank Mechanism of warfarin potentiation by amiodarone: dose and concentration-dependent inhibition of warfarin elimination Eur J Clin Pharmacol 28 1985 257 261
6. U. Martinowitz, J. Rabinovich, D. Goldfarb, A. Many, and H. Bank Interaction between warfarin sodium and amiodarone N Engl J Med 304 1981 671 672
7. A. Rees, J.J. Dalal, P.G. Reid, A.H. Henderson, and M.J. Lewis Dangers of amiodarone and anticoagulant treatment Br Med J (Clin Res Ed) 282 1981 1756 1757
8. A. Hamer, T. Peter, W.J. Mandel, M.M. Scheinman, and D. Weiss The potentiation of warfarin anticoagulation by amiodarone Circulation 65 1982 1025 1029
9. B. McGovern, H. Garan, E. Kelly, and J.N. Ruskin Adverse reactions during treatment with amiodarone hydrochloride Br Med J 287 1983 175 180
10. E.A. Raeder, P.J. Podrid, and B. Lown Side effects and complications of amiodarone therapy Am Heart J 109 1985 975 983
11. B. Cheung, F.M. Lam, and C.R. Kumana Insidiously evolving, occult drug interaction involving warfarin and amiodarone Br Med J 312 1996 107 108
12. L.D. Heimark, L. Wienkers, K. Kunze, M. Gibaldi, A.C. Eddy, W.F. Trager, R.A. O'Reilly, and D.A. Goulart The mechanism of the interaction between amiodarone and warfarin in humans Clin Pharmacol Ther 51 1992 398 407
13. K. Zhang, C. Young, and J. Berger Administrative claims analysis of the relationship between warfarin use and risk of hemorrhage including drug-drug and drug-disease interactions J Manag Care Pharm 12 2006 640 648
14. D.A. Alter, C.D. Naylor, P. Austin, and J.V. Tu Effects of socioeconomic status on access to invasive cardiac procedures and on mortality after acute myocardial infarction N Engl J Med 341 1999 1359 1367
15. S. Schneeweiss, J.A. Rassen, R.J. Glynn, J. Avorn, H. Mogun, and M.A. Brookhart High-dimensional propensity score adjustment in studies of treatment effects using health care claims data Epidemiology 20 2009 512 522
16. J.A. Rassen, J. Avorn, and S. Schneeweiss Multivariate-adjusted pharmacoepidemiologic analyses of confidential information pooled from multiple health care utilization databases Pharmacoepidemiol Drug Saf 19 2010 848 857
17. T. Arnason, P.S. Wells, C. van Walraven, and A.J. Forster Accuracy of coding for possible warfarin complications in hospital discharge abstracts Thromb Res 118 2006 253 262
18. D.S. Raiford, S.P. Gutthann, and L.A.G. Rodriguez Positive predictive value of ICD-9 codes in the identification of cases of complicated peptic ulcer disease in the Saskatchewan hospital automated database Epidemiology 7 1996 101 104
19. C. van Walraven, N. Oake, P.S. Wells, and A.J. Forster Burden of potentially avoidable anticoagulant-associated hemorrhagic and thromboembolic events in the elderly Chest 131 2007 1508 1515
20. P.C. Austin Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples Stat Med 28 2009 3083 3107
21. N. Oake, A. Jennings, A.J. Forster, D. Fergusson, S. Doucette, and C. van Walraven Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis CMAJ 179 2008 235 244
22. B.K. Nallamothu, R.A. Hayward, and E.R. Bates Beyond the randomized clinical trial: the role of effectiveness studies in evaluating cardiovascular therapies Circulation 118 2008 1294 1303